Friday, 20 November 2026
Companies

ADCAN Pharma and M42 sign agreement on cancer drug manufacturing and trials

The Abu Dhabi deal starts with packaging work for Glenmark and aims to register an antibody-drug conjugate cancer treatment in the UAE.

ADCAN Pharma and M42 delegations stand behind an M42 desk at Abu Dhabi Future Health Summit
Photo · ADCAN Pharma

ADCAN Pharma, a UAE drug manufacturer, has signed a memorandum of understanding with the health technology group M42 to work together on making cancer medicines and on clinical research.

The two will look at contract development and manufacturing work through Glenmark Pharmaceuticals, starting with secondary packaging, in which finished medicines are labelled and packed for each market, and with supply for export. Glenmark has already audited the quality of ADCAN’s factory, a step needed before the project can go further.

The next stage is to help register in the UAE an advanced cancer treatment based on an antibody-drug conjugate, which attaches a cancer-killing drug to an antibody so that it reaches cancer cells directly. Releasing batches for export markets could follow, subject to regulatory approval. ADCAN will also support clinical trials run by IROS, M42’s contract research organisation.

Dr Fokion Sinis, chief executive of ADCAN Pharma, and Dr David Kavanagh, acting chief operating officer of M42’s Integrated Health Solutions, signed the agreement at Abu Dhabi Future Health Summit 2026. ADCAN announced it in a statement published on 9 November.

Hamdan Mohamed AlDahmani, chairman of ADCAN Pharma, said: “Our partnership with M42 is an important step in developing advanced pharmaceutical manufacturing capabilities in the UAE and strengthening the sector’s competitiveness in regional and international markets.”

Kavanagh said: “Turning scientific discovery into treatments for patients depends on clinical research and pharmaceutical manufacturing working closely together.”

The photo above was issued by ADCAN Pharma with the announcement.